Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P G Sleph

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Journal of Cardiovascular Pharmacology|January 1, 1997
Glyburide-reversible cardioprotective effects of BMS-180448: functional and energetic considerationsG J Grover, P G Sleph, S Dzwonczyk, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 1, 1991
Effect of potassium channel blockade on the anti-ischemic actions of mechanistically diverse agentsC A Sargent, M A Smith, S Dzwonczyk, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 1, 1989
Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburideG J Grover, J R McCullough, D E Henry, et al.
Cardiovascular Research|November 1, 1995
Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shorteningG J Grover, A J D'Alonzo, T Hess, et al.
Pflugers Archiv : European Journal of Physiology|October 1, 1990
Myosin light-chain phosphorylation and vascular resistance in canine anterior tibial arteries in situS Moreland, L M Antes, D M McMullen, et al.
Journal of Cardiovascular Pharmacology|August 1, 1990
Anti-ischemic activity of the novel benzazepine calcium antagonist SQ 31,486G J Grover, P G Sleph, C S Parham, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1991
Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotectionG J Grover, P G Sleph, S Dzwonczyk, et al.
Circulation Research|October 1, 1991
Specific block of the anti-ischemic actions of cromakalim by sodium 5-hydroxydecanoateJ R McCullough, D E Normandin, M L Conder, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1994
The cardioprotective and electrophysiological effects of cromakalim are attenuated by meclofenamate through a cyclooxygenase-independent mechanismG J Grover, A J D'Alonzo, P G Sleph, et al.
Journal of Cardiovascular Pharmacology|October 1, 1993
Cardioprotective effects of the cyanoguanidine potassium channel opener P-1075C A Sargent, P G Sleph, S Dzwonczyk, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Journal of Cardiovascular Pharmacology|January 1, 1997
Glyburide-reversible cardioprotective effects of BMS-180448: functional and energetic considerationsG J Grover, P G Sleph, S Dzwonczyk, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 1, 1991
Effect of potassium channel blockade on the anti-ischemic actions of mechanistically diverse agentsC A Sargent, M A Smith, S Dzwonczyk, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 1, 1989
Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburideG J Grover, J R McCullough, D E Henry, et al.
Cardiovascular Research|November 1, 1995
Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shorteningG J Grover, A J D'Alonzo, T Hess, et al.
Pflugers Archiv : European Journal of Physiology|October 1, 1990
Myosin light-chain phosphorylation and vascular resistance in canine anterior tibial arteries in situS Moreland, L M Antes, D M McMullen, et al.
Journal of Cardiovascular Pharmacology|August 1, 1990
Anti-ischemic activity of the novel benzazepine calcium antagonist SQ 31,486G J Grover, P G Sleph, C S Parham, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1991
Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotectionG J Grover, P G Sleph, S Dzwonczyk, et al.
Circulation Research|October 1, 1991
Specific block of the anti-ischemic actions of cromakalim by sodium 5-hydroxydecanoateJ R McCullough, D E Normandin, M L Conder, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1994
The cardioprotective and electrophysiological effects of cromakalim are attenuated by meclofenamate through a cyclooxygenase-independent mechanismG J Grover, A J D'Alonzo, P G Sleph, et al.
Journal of Cardiovascular Pharmacology|October 1, 1993
Cardioprotective effects of the cyanoguanidine potassium channel opener P-1075C A Sargent, P G Sleph, S Dzwonczyk, et al.
Pageof 5